241 related articles for article (PubMed ID: 15518540)
1. Atomic mapping of the interactions between the antiviral agent cyanovirin-N and oligomannosides by saturation-transfer difference NMR.
Sandström C; Berteau O; Gemma E; Oscarson S; Kenne L; Gronenborn AM
Biochemistry; 2004 Nov; 43(44):13926-31. PubMed ID: 15518540
[TBL] [Abstract][Full Text] [Related]
2. NMR study of hydroxy protons of di- and trimannosides, substructures of Man-9.
Hakkarainen B; Kenne L; Lahmann M; Oscarson S; Sandström C
Magn Reson Chem; 2007 Dec; 45(12):1076-80. PubMed ID: 18044811
[TBL] [Abstract][Full Text] [Related]
3. Atomic mapping of the sugar interactions in one-site and two-site mutants of cyanovirin-N by NMR spectroscopy.
Sandström C; Hakkarainen B; Matei E; Glinchert A; Lahmann M; Oscarson S; Kenne L; Gronenborn AM
Biochemistry; 2008 Mar; 47(12):3625-35. PubMed ID: 18311923
[TBL] [Abstract][Full Text] [Related]
4. Potent inhibition of HIV-1 fusion by cyanovirin-N requires only a single high affinity carbohydrate binding site: characterization of low affinity carbohydrate binding site knockout mutants.
Chang LC; Bewley CA
J Mol Biol; 2002 Apr; 318(1):1-8. PubMed ID: 12054763
[TBL] [Abstract][Full Text] [Related]
5. Site-specific discrimination by cyanovirin-N for alpha-linked trisaccharides comprising the three arms of Man(8) and Man(9).
Bewley CA; Kiyonaka S; Hamachi I
J Mol Biol; 2002 Sep; 322(4):881-9. PubMed ID: 12270721
[TBL] [Abstract][Full Text] [Related]
6. A solution NMR study of the interactions of oligomannosides and the anti-HIV-1 2G12 antibody reveals distinct binding modes for branched ligands.
Enríquez-Navas PM; Marradi M; Padro D; Angulo J; Penadés S
Chemistry; 2011 Feb; 17(5):1547-60. PubMed ID: 21268157
[TBL] [Abstract][Full Text] [Related]
7. Computational study of the dynamics of mannose disaccharides free in solution and bound to the potent anti-HIV virucidal protein cyanovirin.
Margulis CJ
J Phys Chem B; 2005 Mar; 109(8):3639-47. PubMed ID: 16851402
[TBL] [Abstract][Full Text] [Related]
8. Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition.
Barrientos LG; Matei E; Lasala F; Delgado R; Gronenborn AM
Protein Eng Des Sel; 2006 Dec; 19(12):525-35. PubMed ID: 17012344
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of peptides that bind to cyanovirin-N, a potent human immunodeficiency virus-inactivating protein.
Han Z; Simpson JT; Fivash MJ; Fisher R; Mori T
Peptides; 2004 Apr; 25(4):551-61. PubMed ID: 15165709
[TBL] [Abstract][Full Text] [Related]
10. Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins.
Shenoy SR; O'Keefe BR; Bolmstedt AJ; Cartner LK; Boyd MR
J Pharmacol Exp Ther; 2001 May; 297(2):704-10. PubMed ID: 11303061
[TBL] [Abstract][Full Text] [Related]
11. Solution structure of a cyanovirin-N:Man alpha 1-2Man alpha complex: structural basis for high-affinity carbohydrate-mediated binding to gp120.
Bewley CA
Structure; 2001 Oct; 9(10):931-40. PubMed ID: 11591348
[TBL] [Abstract][Full Text] [Related]
12. Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein.
Mori T; Shoemaker RH; Gulakowski RJ; Krepps BL; McMahon JB; Gustafson KR; Pannell LK; Boyd MR
Biochem Biophys Res Commun; 1997 Sep; 238(1):218-22. PubMed ID: 9299482
[TBL] [Abstract][Full Text] [Related]
13. Epitope mapping of sialyl Lewis(x) bound to E-selectin using saturation transfer difference NMR experiments.
Rinnbauer M; Ernst B; Wagner B; Magnani J; Benie AJ; Peters T
Glycobiology; 2003 Jun; 13(6):435-43. PubMed ID: 12626392
[TBL] [Abstract][Full Text] [Related]
14. Exploiting Uniformly
Nestor G; Anderson T; Oscarson S; Gronenborn AM
J Am Chem Soc; 2017 May; 139(17):6210-6216. PubMed ID: 28406013
[TBL] [Abstract][Full Text] [Related]
15. Solution structure of cyanovirin-N, a potent HIV-inactivating protein.
Bewley CA; Gustafson KR; Boyd MR; Covell DG; Bax A; Clore GM; Gronenborn AM
Nat Struct Biol; 1998 Jul; 5(7):571-8. PubMed ID: 9665171
[TBL] [Abstract][Full Text] [Related]
16. Properties of cyanovirin-N (CV-N): inactivation of HIV-1 by sessile cyanovirin-N (sCV-N).
Gandhi MJ; Boyd MR; Yi L; Yang GG; Vyas GN
Dev Biol (Basel); 2000; 102():141-8. PubMed ID: 10794101
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping.
Yang F; Bewley CA; Louis JM; Gustafson KR; Boyd MR; Gronenborn AM; Clore GM; Wlodawer A
J Mol Biol; 1999 May; 288(3):403-12. PubMed ID: 10329150
[TBL] [Abstract][Full Text] [Related]
18. A monovalent mutant of cyanovirin-N provides insight into the role of multiple interactions with gp120 for antiviral activity.
Fromme R; Katiliene Z; Giomarelli B; Bogani F; Mc Mahon J; Mori T; Fromme P; Ghirlanda G
Biochemistry; 2007 Aug; 46(32):9199-207. PubMed ID: 17636873
[TBL] [Abstract][Full Text] [Related]
19. A model for cell-surface-exposed carbohydrate moieties suitable for structural studies by NMR spectroscopy.
Mares J; Müller JU; Skirgailiene A; Neumoin A; Bewley CA; Schmidt RR; Zerbe O
Chembiochem; 2006 Nov; 7(11):1764-73. PubMed ID: 16952190
[TBL] [Abstract][Full Text] [Related]
20. Computational models explain the oligosaccharide specificity of cyanovirin-N.
Fujimoto YK; Terbush RN; Patsalo V; Green DF
Protein Sci; 2008 Nov; 17(11):2008-14. PubMed ID: 18809850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
